Document Detail

Safety of intravenous immunoglobulin treatment.
MedLine Citation:
PMID:  20408737     Owner:  NLM     Status:  In-Process    
IMPORTANCE OF THE FIELD: Intravenous immunoglobulin (IVIg) is a biologic pharmaceutical that is widely used to treat immunodeficiency conditions and a variety of autoimmune conditions. It is under-recognized that IVIg can be associated with severe complications including death.
AREAS COVERED IN THIS REVIEW: This review will address common mild side effects and extensively discuss the uncommon but serious complications of IVIg. Mild constitutional reactions include headache, fever and rash and severe complications include anaphylaxis, acute renal failure, stroke and myocardial infarction. IVIg has been used to treat autoimmune illnesses for ~30 years and the literature since then is reviewed with special attention to reports in the last 10 years that detail the serious adverse events.
WHAT THE READER WILL GAIN: The reader will understand that mild side effects are common and that these can be ameliorated with pre-treatment medications. They will also become familiar with the risk factors for serious complications so that careful patient and IVIg product selection will result in fewer poor outcomes.
TAKE HOME MESSAGE: IVIg is quite safe across age groups although serious adverse reactions occur particularly in elderly individuals with multiple cardiovascular risk factors and those with preexisting renal failure.
James B Caress; Burton L Kennedy; Kara D Eickman
Related Documents :
6943817 - Survival in temporal arteritis.
6354007 - Terbutaline sulfate and isoproterenol sulfate (metered dose aerosols) in the treatment ...
7970907 - Persistent wheezing and gastroesophageal reflux in infants.
18484427 - Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic option...
23114247 - Do children with high body mass indices have a higher incidence of emesis when undergoi...
23956707 - Analgesic efficacy of peritubal infiltration of ropivacaine versus ropivacaine and morp...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  9     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  971-9     Citation Subset:  IM    
Department of Neurology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gold nanoparticles: opportunities and challenges in nanomedicine.
Next Document:  Investigational melatonin receptor agonists.